These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33547925)

  • 41. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
    Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
    J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease.
    Gonska T; Choi P; Stephenson A; Ellis L; Martin S; Solomon M; Dupuis A; Dorfman R; Zielenski J; Ooi CY; Weiser W; Durie PR; Tullis E
    Chest; 2012 Oct; 142(4):996-1004. PubMed ID: 22423042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spatial and temporal distribution of cystic fibrosis and of its mutations in Brittany, France: a retrospective study from 1960.
    Scotet V; Gillet D; Duguépéroux I; Audrézet MP; Bellis G; Garnier B; Roussey M; Rault G; Parent P; De Braekeleer M; Férec C;
    Hum Genet; 2002 Sep; 111(3):247-54. PubMed ID: 12215837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France.
    Claustres M; Guittard C; Bozon D; Chevalier F; Verlingue C; Ferec C; Girodon E; Cazeneuve C; Bienvenu T; Lalau G; Dumur V; Feldmann D; Bieth E; Blayau M; Clavel C; Creveaux I; Malinge MC; Monnier N; Malzac P; Mittre H; Chomel JC; Bonnefont JP; Iron A; Chery M; Georges MD
    Hum Mutat; 2000; 16(2):143-56. PubMed ID: 10923036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
    Ooi CY; Durie PR
    J Cyst Fibros; 2012 Sep; 11(5):355-62. PubMed ID: 22658665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
    Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
    Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes.
    Castellani C; Quinzii C; Altieri S; Mastella G; Assael BM
    Genet Test; 2001; 5(3):249-54. PubMed ID: 11788092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.
    MacKenzie T; Gifford AH; Sabadosa KA; Quinton HB; Knapp EA; Goss CH; Marshall BC
    Ann Intern Med; 2014 Aug; 161(4):233-41. PubMed ID: 25133359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abnormal expression of the cystic fibrosis transmembrane regulator in chronic sinusitis in cystic fibrosis and non-cystic fibrosis patients.
    Coltrera MD; Mathison SM; Goodpaster TA; Gown AM
    Ann Otol Rhinol Laryngol; 1999 Jun; 108(6):576-81. PubMed ID: 10378526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystic fibrosis: experience in one institution.
    Liu LC; Shyur SD; Chu SH; Huang LH; Kao YH; Lei WT; Cheng CH; Lo CY; Chen CK; Fang LC
    J Microbiol Immunol Infect; 2014 Aug; 47(4):358-61. PubMed ID: 22992393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cystic fibrosis: What's new in South Africa in 2019.
    Zampoli On Behalf Of The Msac M
    S Afr Med J; 2018 Dec; 109(1):16-19. PubMed ID: 30606298
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations.
    Kerem E; Rave-Harel N; Augarten A; Madgar I; Nissim-Rafinia M; Yahav Y; Goshen R; Bentur L; Rivlin J; Aviram M; Genem A; Chiba-Falek O; Kraemer MR; Simon A; Branski D; Kerem B
    Am J Respir Crit Care Med; 1997 Jun; 155(6):1914-20. PubMed ID: 9196095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cystic fibrosis transmembrane conductance regulator gene mutations and glutathione S-transferase null genotypes in cystic fibrosis patients in Brazil.
    Lima CS; Ortega MM; Marson FA; Zulli R; Ribeiro AF; Bertuzzo CS
    J Bras Pneumol; 2012; 38(1):50-6. PubMed ID: 22407040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
    Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis].
    Regard L; Lafoeste H; Martin C; Chassagnon G; Burgel PR
    Rev Pneumol Clin; 2018 Oct; 74(5):279-291. PubMed ID: 30316653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation.
    Ortiz SC; Aguirre SJ; Flores S; Maldonado C; Mejía J; Salinas L
    Mol Genet Genomic Med; 2017 Nov; 5(6):751-757. PubMed ID: 29178639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis.
    Ratkiewicz M; Pastore M; McCoy KS; Thompson R; Hayes D; Sheikh SI
    World J Pediatr; 2017 Apr; 13(2):129-135. PubMed ID: 28194692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.